Table 3.
Outcomes of conservative treatment in patients with grade 2 stage IA EC.
| Authors | Year | Number of cases/patient number | Progestin therapy | Response | Response month | Recurrence | Hysterectomy | Pregnancy | Follow-up time (months) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| Bokhman et al. (15) | 1985 | 8 | Hydroxyprogesterone 500 mg/day for at least 3 months | – | – | – | – | – | – | Regression |
| Kim et al. (16) | 1997 | Patient1 | MA 160 mg/day | NC | – | – | – | – | 8 | NED |
| Sardi et al. (17) | 1998 | Patient1 | MPA 50 mg/day | NC | – | – | Y (minimal myometrial invasion) | N | 20 | NED |
| Zuckerman et al. (18) | 1998 | Patient1 | MPA(not reported) | CR | 2 | N | Y (no lesion) | Y (twin IVF) | Not reported | NED |
| Imai et al. (19) | 2001 | Patient1 Patient2 |
MPA 600 mg/day MPA 600 mg/day |
CR NC |
9 – |
Y (7) – |
N Y (focal adenocarcinoma) |
N N |
Lost to follow 47 |
– NED |
| Kaku et al. (20) | 2001 | Patient1 Patient2 |
MPA 800 mg/day MPA 600 mg/day |
CR NC |
4 – |
N – |
N Y (EA, G2, MI+) |
NFTD N |
19 22 |
NED NED |
| Gotlieb et al. (21) | 2003 | Patient1 | MPA 200 mg for 14 days, every 4 weeks | CR | 3 | Y (40) | Y (EA, G1) | NFTD | 94 | NED |
| Han et a. (22) | 2009 | Patient1 Patient2 |
MPA 500 mg/day MA 80 mg/day |
CR CR |
3 3 |
N N |
N N |
52 42 |
NED NED |
|
| Koskas et al. (23) | 2011 | Patient1 Patient2 Patient3 |
NES 20 mg/day MA 160 mg/day NG 5 mg/day |
CR CR CR |
3 6 3 |
Y (3) N Y (36) |
Refused N Y (EA,G1) |
N Y (twin) N |
12 24 60 |
EA, G1 NED NED |
| Brown et al. (24) | 2012 | Patient1 | LNG-IUS | CR | 3 | N | N | N | 13 | NED |
| Park et al. (25) | 2013 | 23 | MA 160 mg/day or MPA 500 mg/day | 17 (73.9%) | 17 (9–51) | 8 (47.1%) | 5 (45%) | 49 (22–95) | NED | |
| Rossetti et al. (26) | 2014 | Patient1 Patient2 |
MA 160 mg/day MA 160 mg/day |
CR CR |
3 3 |
N N |
Y N |
52 36 | NEDNED | |
| Hwang et al. (27) | 2017 | Patient1 Patient2 Patient3 Patient4 Patient5 |
combined oral MPA (500 mg/day)/LNG-IUS | CR CR PR CR PR |
11 ± 6.2 (6–18) | 1 (20%) | N N N N Y (EA, no MI) |
Yes(missed Abortion) N N N N |
59 19 10 55 69 |
NED NED NED NED NED |
| Pal et al. (28) | 2018 | 8 | LNG-IUS | 3 (37.5%) | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported |
| Maggiore (29) | 2019 | 4 | LNG-IUS | 3 (75%) | 4 ± 0 | 3 (100%) | Y | N | 115.5 ± 2.6 | Not Reported |
| Total | 38/56 (67.9%) | 16/38 (42.1%) |
EA, endometrioid adenocarcinoma; G, grade; IVF, in vitro fertilization; MA, megestrol acetate; MI, myometrial invasion; NED, no evidence of disease; NC, no change; NES, norethisterone; NFTD, normal full-term delivery; NG, nomegestrol; LNG-IUS, levonorgestrel-intrauterine system; Y, yes; N, no.